Erschienen in:
01.11.2017 | Gynecologic Oncology
Comment on: Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
verfasst von:
Thales Paulo Batista, MD, MS
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2017
Einloggen, um Zugang zu erhalten
Excerpt
Hyperthermic intraperitoneal chemotherapy (HIPEC) is certainly a promising treatment option for patients with advanced ovarian cancer, since this disease often remains limited to the peritoneal cavity and this is also the preferred site of recurrence. However, there is insufficient evidence in scientific literature to advocate this approach as a formal therapy for ovarian cancer, and HIPEC still needs to be evaluated by means of randomized trials, which may surely provide additional information on this matter. In this setting, we read with great interest the recently published article by Spiliotis et al. in
Annals of Surgical Oncology 1 describing the first phase III trial exploring use of HIPEC for ovarian cancer. …